zalcitabine has been researched along with acriflavine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambetima, N; Blanquet, D; Hallard, M; Mathé, G; Morette, C; Orbach-Arbouys, S; Pontiggia, P; Triana, K | 1 |
| Blanquet, D; Hage, F; Hallard, M; Mathe, G; Morette, C; Pontiggia, P | 1 |
1 trial(s) available for zalcitabine and acriflavine
| Article | Year |
|---|---|
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
1 other study(ies) available for zalcitabine and acriflavine
| Article | Year |
|---|---|
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-HIV Agents; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Follow-Up Studies; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Stavudine; Vitamin B 12; Zalcitabine; Zidovudine | 2002 |